Figure 1. Disease patterns by 18 F-FDG–PET/CT and WB-DW-MRI. (A) DD by 18 F-FDG–PET/CT; (B) DD by WB-DW-MRI; (C) focal on DD by 18 F-FDG–PET/CT; (D) focal on DD by WB-DW-MRI; (E) micronodular disease by WB-DW-MRI; (F) focal disease by 18 F-FDG–PET/CT before (i) and after (ii) treatment; (G-H... More about this image found in Disease patterns by 18 F-FDG–PET/CT and WB-DW-MRI. (A) DD by 18 F-FDG–PE...

Figure 2. Relation between ADC values, signal intensity in DWI sequences, and BM cellular density during disease course and response to therapy. MGUS, monoclonal gammopathy of undetermined significance. Adapted from Dutoit et al 92 and Ormond et al. 93 More about this image found in Relation between ADC values, signal intensity in DWI sequences, and BM cell...

Figure 1. The distribution of MG in CLL and its relationship to IGHV gene. (A) Distribution of different subtypes of MG. (B) The distribution of lambda and kappa light-chain use in different types of paraproteinemia. (C) Proportion of patients with mutated IGHV in different MG group. (D) Rel... More about this image found in The distribution of MG in CLL and its relationship to IGHV gene. (A) Dis...

Figure 2. Gene mutation spectrum detected by next-generation target sequencing. (A) Gene mutation rate in MG-positive and MG-negative patients with CLL. (B) Mutation rates in patients with different types of paraproteinemia. ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .001. More about this image found in Gene mutation spectrum detected by next-generation target sequencing. (A) ...

Figure 3. Survival analysis of MG-positive and MG-negative patients with CLL. (A) TTFT. (B) PFS. (C) OS. ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .001. More about this image found in Survival analysis of MG-positive and MG-negative patients with CLL. (A) TT...

Figure 4. Subgroup survival analysis of patients with MG stratified by IGHV mutation status. (A) The proportion of patients with MG in each risk group of CLL-IPI. (B-C) PFS and OS in patients with CLL with mutated IGHV . (D-E) PFS and OS in patients with CLL with unmutated IGHV . More about this image found in Subgroup survival analysis of patients with MG stratified by IGHV mutatio...

Figure 5. Survival curve based on first-line treatment subgroups. (A-B) PFS and OS in patients with CLL treated with chemotherapy as first-line treatment. (C-D) PFS and OS in patients with CLL treated with immunochemotherapy. (E-F) PFS and OS in patients with CLL treated with targeted therapy. More about this image found in Survival curve based on first-line treatment subgroups. (A-B) PFS and OS i...

Figure 6. Survival curve according to serum globulin level at diagnosis. (A) TTFT. (B) PFS. (C) OS. ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .001. More about this image found in Survival curve according to serum globulin level at diagnosis. (A) TTFT. (...

Figure 1. One-way deterministic sensitivity analyses. Each row illustrates analytic outcome (ie, change in ICER) results when 1 parameter is varied across its range. Ranges used in analyses are detailed in Table 1 . Blue denotes ICER changes associated with lower values, whereas red denotes ICE... More about this image found in One-way deterministic sensitivity analyses. Each row illustrates analytic ...

Figure 2. Cost-effectiveness acceptability curve of PSAs. Across WTPs of $150 000, $104 000, and $50 000 per QALY, emicizumab favored over standard care in 100%, 66%, and 0% of 10 000 Monte Carlo iterations, respectively. In the low-dose emicizumab scenario, emicizumab is favored in 100% of iter... More about this image found in Cost-effectiveness acceptability curve of PSAs. Across WTPs of $150 000, $...